ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Solid Organ Pancreas Transplantation Offers Superior Glycemic Control Compared to State of the Art Insulin Delivery with Continuous Glucose Monitoring (CGM)

K. R. McCune, G. K. Dube, P. R. Sandoval, L. E. Ratner

Columbia University, New York, NY

Meeting: 2022 American Transplant Congress

Abstract number: 1153

Keywords: Graft function, Pancreas, Pancreas transplantation, Surgery

Topic: Clinical Science » Pancreas » 65 - Pancreas and Islet: All Topics

Session Information

Session Name: Pancreas and Islet: All Topics

Session Type: Poster Abstract

Date: Sunday, June 5, 2022

Session Time: 7:00pm-8:00pm

 Presentation Time: 7:00pm-8:00pm

Location: Hynes Halls C & D

*Purpose: Advanced insulin delivery systems with CGM fail to keep serum glucose within range (70-180 mmol/L) 30-40% of the time resulting in Hgb A1C goals of 6.5-8%, and continue to have issues with severe hypoglycemic events. We wanted to assess how pancreas transplantation performed compared to our competitors.

*Methods: We conducted a retrospective review of pancreas transplantation at our institution from January 1, 2008 through August 1, 2021. All patients 18 years and older who underwent simultaneous kidney pancreas transplant (SPK), pancreas after kidney transplant (PAK), and pancreas transplant alone (PTA) were included. Outcomes were assessed by Hgb A1C level pretransplant (pre), within the first 3 to 5 months posttransplant (post) and the most recent follow up (MR) (avg 62 months SD 75.4 months).

*Results: 133 patients underwent pancreas transplantation during the study period, 85 SPK (62%) 39 PAK (30%) and 11 PTA (8%). 19 (14%) patients suffered pancreas graft loss in the first year and were excluded from the analysis. Overall, 1, 3, and 5-year graft survival was 86%, 84% and 82% respectively. Of the 114 patients remaining, 96 (84%) were type 1 diabetes diabetics (T1D) and 18 (16%) were type 2 diabetics (T2D). 9 patients have resumed antihyperglycemic therapy not meeting UNOS criteria for failure. There have been 7 graft failures within the study period, and 8 patients have died (&gt5 years posttransplant). The average HgbA1C pre, post, and MR were 8.3% (SD 1.7) and 5.1% (SD 0.61) (p=0.00026) and 5.3% (SD 0.63) (p=0.91) (fig 1). Of the grafts studied, all had a Hgb A1C of 7% or less. 86% had a Hgb A1C of less than 6% in the post and most recent assessment. There was no significant difference between Hgb A1C outcomes from T1D vs T2D groups. There were no severe hypoglycemic events of patients with functioning grafts.

*Conclusions: Solid organ pancreas transplantation offers superior glycemic control compared to advanced insulin delivery systems. Staying within range is clinically challenging with exogenous insulin regimens due to balancing individual risk of severe hypoglycemic events, leading to Hgb A1C of greater than 7% in most series, a goal that is easily surpassed durably in pancreas transplantation.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

McCune KR, Dube GK, Sandoval PR, Ratner LE. Solid Organ Pancreas Transplantation Offers Superior Glycemic Control Compared to State of the Art Insulin Delivery with Continuous Glucose Monitoring (CGM) [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/solid-organ-pancreas-transplantation-offers-superior-glycemic-control-compared-to-state-of-the-art-insulin-delivery-with-continuous-glucose-monitoring-cgm/. Accessed May 30, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences